Physician profile
Christopher Wright
NPI 1790003267
$4,551.51
in general payments reported to CMS, 2019-2025
27 companies · $704 in 2025
The $704 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $223 · 2021: $656 · 2022: $423 · 2023: $1,078 · 2024: $382 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,534 · Travel and Lodging: $619 · Education: $11.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.01 |
| Travel and Lodging | $619.19 |
| Education | $11.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,900.47 | 2019-2025 | Ams 700 Cxr Rte Kit, General - Erectile Dysfunction, Ams 700 |
| Royal Biologics, INC. | $572.51 | 2019 | |
| Procept Biorobotics Corporation | $341.81 | 2020-2022 | |
| Ethicon US, LLC | $271.00 | 2024-2025 | Stratafix, Surgicel Nu-Knit, Echelon Flex |
| Intuitive Surgical, INC. | $188.28 | 2023 | Da Vinci Surgical System |
| Kerecis Limited | $163.95 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Astellas Pharma US INC | $141.25 | 2019-2021 | |
| Coloplast Corp | $136.73 | 2021-2024 | |
| Axonics, INC. | $120.06 | 2022-2024 | Bulkamid, Axonics |
| Olympus America INC. | $102.22 | 2022-2025 | Itind System |
| Myovant Sciences INC. | $76.81 | 2021-2022 | |
| Urogen Pharma, INC. | $72.18 | 2021 | |
| Calyxo, INC. | $69.42 | 2023-2024 | Cvac Aspiration System |
| Janssen Biotech, INC. | $52.71 | 2019-2021 | |
| Laborie Medical Technologies Corp. | $48.93 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $48.77 | 2024-2025 | Eligard, Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $47.55 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $31.07 | 2025 | Erleada |
| Endo Pharmaceuticals INC. | $29.23 | 2021-2022 | |
| Pfizer INC. | $28.10 | 2019 | |
| Seapearl East, INC | $22.06 | 2023 | |
| Sumitomo Pharma America, INC. | $18.55 | 2025 | Gemtesa |
| Blue Earth Diagnostics | $16.61 | 2024 | |
| Urovant Sciences INC | $14.72 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $14.33 | 2019 | |
| Travere Therapeutics, INC. | $11.35 | 2025 | Thiola |
| Metuchen Pharmaceuticals | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.